Evidence map›Paper›PMID 25002943›Full record

ArticleRare tumors2014

Proton beam therapy for a patient with a giant thymic carcinoid tumor and severe superior vena cava syndrome.

Kaori Sugawara, Masashi Mizumoto, Haruko Numajiri, Toshiki Ohno, Kayoko Ohnishi, Hitoshi Ishikawa, Toshiyuki Okumura, Hideyuki Sakurai

Open access · goldAbstract readCase Reports
In one paragraph

Article in Rare tumors, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kaori SugawaraDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Masashi MizumotoDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Haruko NumajiriDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Toshiki OhnoDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Kayoko OhnishiDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Hitoshi IshikawaDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Toshiyuki OkumuraDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
Hideyuki SakuraiDepartment of Radiation Oncology, University of Tsukuba , Ibaraki, Japan.
University of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surgical resection is the first choice for treatment of a thymic carcinoid tumor and radiotherapy is often performed as adjuvant therapy. Here, we report a case of an unresectable and chemoresistant thymic carcinoid tumor that was treated successfully using standalone proton beam therapy (PBT). The patient was a 66-year-old woman in whom surgical resection of the tumor was impossible because of cardiac invasion. Therefore, chemotherapy was administered. However, the tumor grew to 15 cm in diameter and she developed severe superior vena cava (SVC) syndrome. She was referred to our hospital and received PBT at a dose of 74 GyE in 37 fractions. PBT was conducted without severe early toxicities. After PBT, the tumor mildly shrunk to 13 cm in diameter and SVC syndrome almost disappeared. Subsequently, the tumor has continued to decrease in size slowly over the last 2 years and late toxicities have not been observed. Our experience with this case suggests that PBT may be effective for an unresectable thymic carcinoid tumor.

Indexed as

mediastinal tumorproton beam therapyradiationsuperior vena cava syndromethymic carcinoid tumor

Identifiers

PMID25002943
PMCPMC4083663
OpenAlexW2059324428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.